Actinium reports long-term safety data for Actimab-A plus CLAG-M in relapsed or refractory AML
ATNM•Actinium Pharmaceuticals released a Phase 1 abstract evaluating long-term safety of Actimab-A with CLAG-M chemotherapy in relapsed or refractory AML, with results scheduled for presentation at the American Society of Hematology annual meeting on December 13, 2026.
1. Safety data presentation
The Phase 1 abstract evaluates long-term safety of Actimab-A with CLAG-M chemotherapy in relapsed or refractory acute myeloid leukemia. The findings support further evaluation across mutations, with follow-up assessing blood-count recovery and delayed organ toxicity.
